← Akero Therapeutics, Inc. (AKRO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Akero Therapeutics, Inc. (AKRO)
Pharmaceutical Preparations · market cap $4.5B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Akero Therapeutics (AKRO) is a clinical-stage pharmaceutical company with 74 employees and a ~$4.5B market cap, focused exclusively on NASH (nonalcoholic steatohepatitis). Its lead asset, efruxifermin (EFX), is in Phase 3 development for NASH, with a Phase 2 program also listed in the pipeline. The company has no revenue, is burning roughly $247M annually on R&D, and carries a valuation that is entirely predicated on EFX's clinical and regulatory success.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| EFX | Phase 2 | NASH - Nonalcoholic Steatohepatitis |
| Efruxifermin | Phase 3 | NASH - Nonalcoholic Steatohepatitis |
Price & technical context
3-month
+26.4%
6-month
+0.2%
12-month
+84.0%
52-wk range
$21.87–$57.56
vs 50-day MA
+3.0%
vs 200-day MA
+13.4%
Realized vol
86.1%
Max drawdown
-41.3%
Daily closes through 2025-12-09. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AKRO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.